



RECEIVED


OCT 30 2000

TECH CENTER 1600/2300

PATENT

ATTORNEY DOCKET NO. 50010/007006

1636
#1/00
Dica

| | |
|--|--|
| Certificate of Mailing: Date of Deposit: <u>October 23, 2000</u> | |
| I hereby certify under 37 C.F.R. § 1.8(a) that this correspondence is being deposited with the United States Postal Service as first class mail with sufficient postage on the date indicated above and is addressed to the Assistant Commissioner for Patents, Washington, D.C. 20231. | |
| Nicky McKinnon |  |
| Printed name of person mailing correspondence | Signature of person mailing correspondence |

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicant: Richard F Selden *et al.*

Art Unit: 1636

Serial No.: 09/328,130

Examiner: R. Schwartzman

Filed: June 8, 1999

Title: *In Vivo* Production and Delivery of Erythropoietin or Insulinotropin for Gene Therapy

Assistant Commissioner for Patents
Washington, D.C. 20231

REPLY TO RESTRICTION REQUIREMENT

In reply to the Restriction Requirement that was mailed in the above-captioned case on September 28, 2000, applicants elect the claims of Group I, claims 108-185.

Although no fees are believed to be due, if there are any charges or credits, please
apply them to Deposit Account No. 03-2095.

Respectfully submitted,

Date: October 20, 2000 Susan M. Michaud
Susan M. Michaud, Ph.D.
Reg. No. 42,885

Clark & Elbing LLP
176 Federal Street
Boston, MA 02110
Telephone: 617-428-0200
Facsimile: 617-428-7045

50010.007006 Reply to Restriction Requirement.wpd